Blog
PPHC grows revenue 13% and holds its targets, MeiraGTx’s cash lasts into 2028
PPHC grows revenue 13% and sticks to its full-year targets, and MeiraGTx says its cash lasts into 2028

Companies that put the everyday investor first
Every company in this email has chosen to talk directly to everyday investors, not just the big funds. Here is what they have been up to this week.
Deep dive 01: Public Policy Holding Company (PPHC)
PPHC grows revenue 13% and sticks to its full-year targets
On Monday 9 November, after the US market closed, Public Policy Holding Company (PPHC) reported its third-quarter results (all growth figures below are year on year, against the same period of 2025). Revenue rose 13.2% to US$55.2m, from US$48.8m. Organic growth, which strips out the effect of businesses it has bought, was 5.1%. Adjusted EBITDA rose 11.1% to US$12.8m, a margin of 23.2%. Over the first nine months, revenue was US$157.5m, up 15.2%. The company reaffirmed its full-year 2026 guidance of revenue of US$213m to US$216m, adjusted EBITDA of US$48.5m to US$50.5m and organic growth of about 5%, and it completed its acquisition of Reevemark on 1 November.
For a shareholder, the interest is a business growing both by buying firms and from its existing client work, while holding its targets for the year. The balance: net debt rose to US$21.4m at 30 September, from US$5.2m three months earlier at 30 June, although leverage remains low with headroom for further acquisitions.
US$55.2m Q3 revenue (+13.2%) · US$12.8m adjusted EBITDA (+11.1%) · US$213–216m FY2026 revenue guidance (reaffirmed)
Deep dive 02: MeiraGTx (NASDAQ: MGTX)
MeiraGTx says its cash lasts into 2028, with a first European filing planned for December
On Thursday 12 November, MeiraGTx reported third-quarter results (comparisons below are with the third quarter of 2025). It held US$184.7m of cash at 30 September and said that, including a further US$95m upfront payment from its partner Hologen, this funds the business into the second half of 2028. That runway does not count up to US$135m of potential near-term milestone payments from Eli Lilly. Revenue was US$4.8m, up from US$0.4m, research and development spending rose to US$39.3m from US$32.5m, and the net loss was US$51.3m, or US$0.53 a share. On the pipeline, it plans to submit bota-vec, its gene therapy for an inherited form of sight loss (X-linked retinitis pigmentosa), to the European Medicines Agency in December 2026, subject to the EMA confirming the date, with a US filing expected in the first quarter of 2027.
For a shareholder, a longer cash runway means less pressure to raise money soon, and the planned filings provide concrete milestones on its path to launching bota-vec. The balance: MeiraGTx is still loss-making, and a filing does not mean an approval is guaranteed.
US$184.7m cash at 30 September · H2 2028 cash runway extends into · Dec 2026 EMA submission for bota-vec planned
Also this week
Premier American Uranium: US$5m investment at a premium
On 10 November Premier American Uranium completed a US$5m strategic investment by DISA Uranium: 9,326,000 subscription receipts at C$0.75 each, a 41.5% premium to the 14 September closing price, equal to about 8.88% of the company once converted. The money sits in escrow until Premier American completes the sale of four Colorado projects to DISA, and goes back to DISA if that has not happened by 13 June 2027. Final TSX Venture Exchange approval is still needed. Separately, IsoEnergy raised its holding to about 22.1%. More.
Eden BioSolutions: US green light for Mevalone Delta
On 13 November Eden BioSolutions said the US Environmental Protection Agency has granted federal registration for Mevalone Delta, a product from its Mevalone crop-protection range, with Sipcam Agro USA as distributor. Individual US states still need to register it before it can be sold there. More.
Tharisa: Shares now also trade in Namibia
On 9 November Tharisa’s shares began trading on the Namibia Securities Exchange under the symbol THR, a secondary listing aimed at giving Namibian investors access. Johannesburg remains its main listing. More.
Aberdeen Asia Focus: First dividend of the new year
On 10 November the trust declared a first interim dividend of 1.61p a share for the year to July 2027, up from 1.60p for the same dividend last year. The shares go ex-dividend on Thursday 19 November, the record date is Friday 20 November and payment is on 18 December. It also bought back 324,000 of its own shares on 11 and 12 November. More.
Cordiant is now Corilis: New name, same ticker
On 13 November Cordiant Digital Infrastructure began trading as Corilis Digital Infrastructure, after 99.94% of votes cast at its 11 November meeting backed the change. The ticker (CORD) is unchanged. More.
Ecora Royalties: Directors buy shares
On 9 November Ecora said its chief executive, Marc Bishop Lafleche, bought 18,000 shares on 5 November and its chief financial officer, Kevin Flynn, bought 5,625 shares on 6 November, at around 140p to 141p. More.
Explainer: What is a “cash runway”?
A company that is not yet making a profit, like many drug developers, spends more cash each year than it brings in. Its cash runway is how long the money it has (plus any it is confident of receiving) will last at its current rate of spending before it needs to raise more. A longer runway matters to shareholders because raising money usually means issuing new shares, which shrinks each existing holder’s slice. The balance: a runway is a forecast, and it can shorten if spending rises or expected payments arrive late.
Happening this week (Mon 16 – Fri 20 November)
Monday 16 Nov: China October activity data (industrial output, retail sales), 02:00 UK time. Marex dividend record date (US$0.16, paid 2 December). MeiraGTx gives an oral presentation on its AAV-BDNF programme. Fed Chair Kevin Warsh speaks at the San Francisco Fed, 17:00 UK time.
Tuesday 17 Nov: UK labour market data, 07:00. Imperial Brands full-year results. Home Depot third-quarter results before the US open. US retail sales for October, 13:30 UK time, and industrial production, 14:15. Grid Metals annual and special meeting (Toronto, 11:00 ET). Phoenix Copper presents at the Mello2026 investor event (also Wed 18 Nov). PPHC at the Stephens Annual Investment Conference (17 to 19 Nov). Nvidia third-quarter results, around 21:20 UK time, its first under interim CEO Colette Kress.
Wednesday 18 Nov: UK consumer price inflation for October, 07:00. British Land, Experian and SSE half-year results. Target, Lowe’s and TJX third-quarter results before the US open. US housing starts, 13:30 UK time. Bank of England Governor Andrew Bailey speaks in London, 15:00. US Federal Reserve minutes from its October meeting, 19:00 UK time.
Thursday 19 Nov: Walmart third-quarter results, 12:00 UK time. US weekly jobless claims and Philadelphia Fed survey, 13:30 UK time. Aberdeen Asia Focus goes ex-dividend (1.61p).
Friday 20 Nov: UK retail sales and public sector finances for October, 07:00. ECB President Christine Lagarde speaks at the European Banking Congress, 08:30 UK time. Aberdeen Asia Focus dividend record date.
From the Collective
Rates are rising just as the oil shock fades. Could 2027 look different?
This week’s Collective note made the case that central banks may be tightening in response to an inflation problem that is already starting to ease. Interest rates are going up because recent inflation figures were pushed higher by this year’s oil spike, but oil prices have since fallen sharply. Because inflation compares prices with a year earlier, the note argues that once this spring’s very high oil prices drop out of the comparison, headline inflation could fall quickly in the first half of 2027, and long-term borrowing costs could ease with it. If that happens, the businesses most exposed to UK interest rates and the housing market, which have been out of favour, could be among those that benefit. The note was candid that bond markets have not yet bought this view, and that oil remains vulnerable to headlines.
Mortgage Advice Bureau, a Curation Connect client, sits right on that fault line: it is a network of mortgage advisers whose business depends on how many people buy, move and remortgage. This week (11 November) it rebranded as Mab, moving more than 2,100 advisers to the new name, while its listing and ticker stay the same. The balance: in a separate trading update on 9 September, the company lowered its 2026 profit expectations because the fall in rates and the recovery in house purchases it had expected had not arrived.
Mortgage Advice Bureau on CurationAI.
Best Content Shared This Week
📚 Nvidia vs Anthropic: Where Is the AI Value?
Why Read? Richard Windsor argues that the recent AI sell-off has created a striking valuation disconnect between Nvidia and Anthropic. Despite strong demand and substantial cash generation, Nvidia trades at less than 10x forecast 2027 earnings, while Anthropic is attracting IPO interest at a $1.5tn valuation. The piece examines why Nvidia’s leadership and governance risks may be overshadowing its fundamentals, while Anthropic faces growing competition and questions over the durability of its model economics. A useful look at where the risk and reward now sit across the AI value chain.
Radio Free Mobile · Read here.
📚 Evolv: The Shift Towards Recurring Revenue
Why Read? Evolv expects revenue growth of at least 20% in 2027, despite a 3–4 percentage point headwind from changes to its pricing model. The shift moves more revenue from upfront hardware sales into recurring software and services, with annual recurring revenue expected to grow faster than reported sales. With Q3 revenue reaching a record $47.3m, positive free cash flow and a $326m contracted revenue backlog, the key question is whether this transition can deliver more predictable growth and stronger long-term margins.
Seeking Alpha · Read here.
New Showcases
NovaGen Group
- NovaGen Group is a longevity and regenerative medicine company developing treatments designed to restore immune function and slow age-related decline. Combining cell-based therapies, proprietary research and a planned international network of longevity clinics, the company aims to build a scalable healthcare platform addressing the growing demand for treatments associated with ageing. Having treated more than 1,000 clients, NovaGen is pursuing further clinical development and a proposed merger with Nasdaq-listed VEEA, which could provide access to public markets and additional health technology infrastructure. Its longer-term potential rests on translating early research into clinically validated treatments and scaling its international operations. Read more.
THIS ARTICLE DOES NOT CONSTITUTE ANY FORM OF ADVICE OR RECOMMENDATION AND IS NOT INTENDED TO BE RELIED UPON IN MAKING ANY INVESTMENT DECISIONS. Curation is an information service provided by Curation Corporation. Liability Your investments are your responsibility. No liability whatsoever is accepted by Curation Corporation Limited or any Curation Corporation company of their respective directors, officers, employees or analysts for any loss, whether direct, indirect, special, incidental or consequential, arising whether directly or indirectly as a result of the recipient acting or not acting on any information in any Curation publication, including, without limitation, lost profits arising from the use of the Curation service or any of its publications. We have no liability for any loss of profit, loss of revenue, loss of business, business interruption, loss of opportunity or any indirect, special or consequential loss; any losses which arise from any event beyond our reasonable control; any losses which could not reasonably have been anticipated; or your inability to access and/or use the Curation service or the website. We do not exclude or limit in any way our liability to you where it would be unlawful to do so. Disclaimer Curation publications are provided for general information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument or investment. This document does not constitute, and should not be interpreted as, investment advice. You must carry out your own independent research and obtain suitable professional advice before making any investment decision. The Curation publications do not take the specific needs, investment objectives and financial situation of any particular individual into consideration and we cannot state whether any investment mentioned is suitable for you. You should not base any investment decision solely on the basis of the information we publish or provide to you. Always be aware of market risks, never invest money you cannot afford to lose. All investments can go down as well as up. Investing in securities entails risks. Potential Conflicts of Interest Curation or its respective directors, officers, employees, contributors and clients may have or take positions in the securities, entities or investments mentioned in the Curation publications. Any of these circumstances could create, or be perceived as creating, conflicts of interest. Privacy and Registration All information received from you and your use of the Curation service and the website will be used by Curation Corporation Limited in accordance with our Privacy Policy. Please read this for details of how we may process your personal data. On registration for the Curation service, you must provide us with accurate, complete registration information and it is your responsibility to update and maintain changes to your information. Curation, a trading name of Curation Corporation Limited, is entitled to rely on any information you provide to us. Read our full T&Cs, disclaimers and privacy notice. Contact us at info@curationcorp.com , Curation Corporation Limited, 42-46 Princelet St, London, E1 5LP, UK Read our Disclaimers.
Stock ideas your AI can't see.
Powered by a $250bn AUM investor network. Ask about the companies you follow and get bull case, bear case, catalysts and risks, free to start.
Articles you might like
Go to blog →
Someone has to want to buy the shares. Then someone has to want to keep them.
Nirav Karia talks about why rebuilding the UK IPO market means treating retail investors as long-term owners, not just an exit for existing shareholders.

Buybacks, a steady outlook and a digital leap
Super Group launches a US$150m buyback, Nomad Foods holds its outlook, and VEON raises its 2026 guidance as digital services pass a quarter of revenue

Nick Finegold on AI and the Future of Work at SALT London
Curation co-founder Nick Finegold discussed AI and the future of work at SALT London, exploring technology’s potential implications for financial services, investor relations and retail investors.